Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD3/CD28 stimulated/primed autologous Ts |
Synonyms | |
Therapy Description |
T cells that have been sensitized to vaccine tumor antigen(s) in vivo, then collected from the patient, costimulated with antibodies to the T-cell cell surface proteins CD3 and CD28 and expanded, then re-infused to the same patient (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD3/CD28 stimulated/primed autologous Ts | ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells | T cells that have been sensitized to vaccine tumor antigen(s) in vivo, then collected from the patient, costimulated with antibodies to the T-cell cell surface proteins CD3 and CD28 and expanded, then re-infused to the same patient (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01312376 | Phase I | Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Terminated | USA | 0 |